According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
Chiasma (NASDAQ:CHMA) opened at 3.00 on Tuesday. The stock has a 50 day moving average price of $2.76 and a 200 day moving average price of $3.70. The firm’s market cap is $73.07 million. Chiasma has a 12 month low of $2.40 and a 12 month high of $24.78.
Chiasma (NASDAQ:CHMA) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.47. On average, equities analysts expect that Chiasma will post ($3.14) earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the stock. A.R.T. Advisors LLC bought a new stake in Chiasma during the second quarter valued at $441,000. Opaleye Management Inc. raised its stake in Chiasma by 115.0% in the second quarter. Opaleye Management Inc. now owns 43,000 shares of the company’s stock valued at $443,000 after buying an additional 23,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Chiasma by 25.7% in the second quarter. Vanguard Group Inc. now owns 426,477 shares of the company’s stock valued at $1,233,000 after buying an additional 87,259 shares in the last quarter. MPM Asset Management LLC raised its stake in Chiasma by 1.0% in the second quarter. MPM Asset Management LLC now owns 5,736,296 shares of the company’s stock valued at $16,578,000 after buying an additional 54,752 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in Chiasma during the first quarter valued at $2,113,000. Institutional investors own 58.76% of the company’s stock.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.